A risk-enhancing factor that counts? (weighted — a single unconfirmed hs-CRP does not count until repeated) One or more present
risk-borderline-enhancersNo one has reached this rule yetStatin reasonable to start now — no further testing needed to decide
No clinician has signed off this rule yet. It reflects our reading of the guidelines cited below, which has not been independently checked.
Word for word, as generated for the example person below. Figures in the text are theirs.
Statin therapy is reasonable to start now.
Your estimated 10-year PREVENT ASCVD risk is 4.9% (the "borderline" 3%–5% band), and you have risk-enhancing factors that tip that decision toward treatment: Elevated lipoprotein(a) — 78 mg/dL. The guideline says risk enhancers move a borderline-risk person toward a statin without needing further testing.
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Class 2a
“Borderline risk + high Lp(a)” — an illustrative profile, not a real user.
Asked after: 10-year risk 3% to under 5%
Cited by the recommendations above.
For practising clinicians. Endorse it, propose a change, or dispute it. We verify every reviewer before a review is shown, and a review stays attached to the version of the rule you saw — if the rule changes, the page says so. You'll be asked to declare any relevant interests; they're shown with your review.
Log in or create an account to submit a review. An account is how we tie a review to a person we can verify.
Runs in lib/engine/lipidPathway.ts as risk-borderline-enhancers.